Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme to Sell Third Wave s Colorectal Cancer PGx Test in North America

NEW YORK, Oct. 27 (GenomeWeb News) - Genzyme Genetics will sell Third Wave's Invader UGT1A1 molecular assay to identify colorectal cancer patients who could be considered for, or currently undergoing, chemotherapy with Camptosar, the companies said today.

Besides launching the test in North America, Genzyme will begin a "direct education program" aimed at oncologists and pathologists in that market the companies said.

The Invader UGT1A1 molecular assay identifies patients who may be at increased risk for adverse reactions to Camptosar, developed by Pharmacia, by detecting variations in the UGT1A1 gene that have been associated with that risk.

 

A clinical study indicated that patients with one of these variations have a greater than nine-fold increased risk of experiencing toxicity from Camptosar than patients without the variation, the companies said. As such, Camptosar's labeling was recently updated to include dosing recommendations based on a patient's UGT1A1 status.

Wave said it will make the assay available to its current customers.

 

Financial details were not disclosed.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.